Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oruka Therapeutics, Inc. - Common Stock (NQ:ORKA)

68.41 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oruka Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
From Oruka Therapeutics, Inc.
Via GlobeNewswire
These stocks are gapping in today's session ↗
Via Chartmill
MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades ↗
Via Stocktwits
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors ↗
This Menlo Park biotech, focused on monoclonal antibody therapies, reported a notable insider sale amid a year of dramatic share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health. 
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials. 
Via The Motley Fool
Topics Regulatory Compliance
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces New Board Member and Board Transition
Appoints accomplished commercial leader Chris Martin to its Board of Directors 
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
AutoZone To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Oruka Therapeutics Inc (NASDAQ:ORKA) Reports Q3 2025 Results, Beats EPS Estimates and Provides Clinical Pipeline Updates ↗
Oruka Therapeutics reports Q3 2025 results, beating EPS estimates. With a strong $500.9M cash position, the biotech advances its clinical pipeline for ORKA-001 and ORKA-002. 
Via Chartmill
News headline image
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Insider Report: The Bulls Can Thank Tech ↗
 
Via Benzinga
News headline image
Oruka Therapeutics to Present at Multiple November Investor Conferences
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stock Market Today: Nasdaq, S&P 500 Futures Rise As Government Enters 2nd Week Of Shutdown—Plug, Lithium Americas, UiPath In Focus ↗
U.S. stock futures rose on Monday following Friday’s mixed moves. Futures of major benchmark indices were higher. 
Via Benzinga
Topics Stocks
News headline image
Constellation Brands, Aehr Test Systems And 3 Stocks To Watch Heading Into Monday ↗
US stock futures up, focus on Constellation Brands, SkyWater Tech, Aehr Test Systems, Oruka Therapeutics and VCI Global earnings. 
Via Benzinga
News headline image
MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment ↗
MoonLake Immunotherapeutics stock crashed Monday after the company posted mixed results for its skin disease drug. 
Via Investor's Business Daily
News headline image
Wednesday's session: gap up and gap down stocks ↗
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Oruka Therapeutics, Up 20%, Is Trying To Take On AbbVie's Biggest Moneymaker ↗
Shares skyrocketed after the company said its drug has a half-life of about 100 days. 
Via Investor's Business Daily
News headline image
Discover the top movers in Wednesday's pre-market session. ↗
Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.